Brookfield Asset Management Inc. Argenx Se Transaction History

Brookfield Asset Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Sep 25, 2023	BUY	$334.23 - $403.65 $5.62 Million - $6.79 Million	16,810 New	16,810 $6.26 Million
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $1.18 Million - $1.42 Million	-3,525 Reduced 17.33%	16,810 $6.26 Million
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $5.48 Million - $6.44 Million	-16,015 Reduced 44.06%	20,335 $7.7 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $3.65 Million - $4.21 Million	10,646 Added 41.42%	36,350 $12.8 Million
Q2 2022 Nov 16, 2022	SELL	$269.58 - $378.88 $2.87 Million - $4.03 Million	-10,646 Reduced 29.29%	25,704 $9.74 Million
Q2 2022 Aug 15, 2022	BUY	$269.58 - $378.88 $6.34 Million - $8.91 Million	23,528 Added 1081.25%	25,704 $9.74 Million
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $1.16 Million - $1.6 Million	-4,563 Reduced 67.71%	2,176 $686,000
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $628,071 - $815,146	2,309 Added 52.12%	6,739 $2.36 Million
Q3 2021 Nov 16, 2021	BUY	$295.0 - $350.58 $868,480 - $1.03 Million	2,944 Added 198.12%	4,430 $1.34 Million
Q2 2021 Aug 17, 2021	BUY	$257.11 - $319.92 $382,065 - $475,401	1,486 New	1,486 $447,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.